The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The CAR-T Therapy Market In 2026 And What Value Is Projected For 2030?
The car-t therapy market has experienced substantial expansion in recent years. It is projected to increase from $2.98 billion in 2025 to $3.45 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.9%. This past growth can be ascribed to factors such as the restricted availability of personalized immunotherapy, the high expense of initial car-t treatments, the reliance on hospital-based cell processing, emerging regulatory frameworks, and limited patient understanding of car-t therapy.
The car-t therapy market size is anticipated to undergo significant expansion in the coming years. Its value is projected to reach $6.08 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.2%. This expected growth during the forecast period stems from factors such as technological progress in t-cell engineering, increasing investment in cancer research, the expansion of commercial car-t production facilities, a rise in regulatory authorizations, and growing partnerships between biopharma firms and academic bodies. Prominent trends for the forecast period include the increasing use of car-t therapies in blood cancers, the creation of antigen-specific car-t treatments, greater utilization of combination therapy methods, the broadening of clinical studies and research efforts, and a focus on lowering treatment costs and boosting availability.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6670&type=smp
What Drivers Are Influencing The CAR-T Therapy Market?
The expanding occurrence of cancer is projected to fuel the growth of the CAR-T therapy market moving forward. This expanding occurrence refers to an increasing count of diagnosed cancer cases within a specific demographic or geographical area over a particular timeframe. The heightened prevalence of cancer has stimulated both research and investment in cancer treatments, including cellular immunotherapies. These therapeutic approaches represent a significant advancement in oncology and are particularly vital for addressing the needs of cancer patients. For instance, data from July 2024, as per the Australian Institute of Health and Welfare, an Australia-based government agency, indicates that cancer diagnoses in Australia climbed from 160,570 in 2022 to 164,694 in 2023, showcasing a considerable rise over the past year. This pattern underscores the escalating prevalence of cancer across the nation. Consequently, the rising prevalence of cancer is driving the expansion of the CAR-T therapy market.
What Are The Key Segments Of The CAR-T Therapy Market?
The car-t therapy market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications
Subsegments:
1) By Monotherapy: CD19-targeted CAR-T Therapy, BCMA-Targeted CAR-T Therapy
2) By Combination Therapy: CAR-T Therapy With Immune Checkpoint Inhibitors, CAR-T Therapy With Other Targeted Therapies, CAR-T Therapy With Chemotherapy Or Radiotherapy
What Key Trends Are Influencing The Development Of The CAR-T Therapy Market?
Leading companies within the CAR-T therapy sector are prioritizing the creation of sophisticated diagnostic instruments to boost individualized treatment approaches and elevate patient results. These tools encompass various instruments, devices, or software designed for recognizing and evaluating illnesses, conditions, or health concerns in people, potentially involving tests, imaging technologies, or laboratory analyses that offer crucial insights into a patient’s health condition for precise diagnosis and strategic treatment development. An illustration of this trend is Eurofins Viracor, a clinical diagnostic laboratory situated in the US, which introduced the ExPeCT Expansion and Persistence of CAR T Assay in February 2023. This assay aims to assist clinicians in gaining a clearer understanding of how CAR-T therapy is functioning for their patients. It provides substantial advantages for overseeing patients receiving CAR T cell therapy by facilitating the continuous tracking of CAR T cell expansion and persistence, delivering real-time information crucial for assessing treatment effectiveness and guiding patient care. Furthermore, the assay assists in detecting patients susceptible to treatment failure because of insufficient CAR T cell dynamics, thereby enabling prompt interventions that could enhance clinical outcomes in blood cancers.
Who Are The Leading Companies Operating In The CAR-T Therapy Market?
Major companies operating in the car-t therapy market are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., CARsgen Therapeutics, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune (UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Precision BioSciences, Bellicum, GlaxoSmithKline plc
Read the full car-t therapy market report here:
https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The CAR-T Therapy Market?
North America was the largest region in the CAR-T therapy market in 2025. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored CAR-T Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=6670&type=smp
Browse Through More Reports Similar to the Global CAR-T Therapy Market 2026, By The Business Research Company
Cardiac Arrhythmia Monitoring Devices Market Report 2026
Cardiovascular Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report
Wearable Heart Monitoring Devices Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model